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Looking to nature for medicine is nothing new – we have been doing it for tens of thousands of years and although modern pharmaceutical science has come a long way from those ancient roots, nature is and will always be an important source of useful compounds and inspiration. Dismiss-
ing nature in this regard is a huge mistake as evolution is the greatest problem solver and the myriad com-
pounds produced by the immense variety of species we share the planet with have been honed by three 
billion years of trial and error. However, with every bit of habitat that disappears under the plough or 
concrete we impoverish nature and deprive ourselves of potential medicines.
The preservation of biodiversity is perhaps the single most important building block for achieving the 17 
Sustainable Development Goals set by the United Nations. For many of these goals, the importance of 
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preserving biodiversity is obvious, e.g.SDG-2 (Zero Hun-
ger), SDG-13 (Climate Action), SDG-14 (Life below Water), 
and SDG-15 (Life on Land). This argument holds true for 
the other global goals including, but not limited to, SDG-3 
(Good Health and Well-being), SDG-10 (Reducing Inequal-
ities), and SDG-12 (Responsible Consumption and Produc-
tion). Preserving biodiversity in many landscapes and natu-
ral habitats free for people to enjoy and access both locally 
and worldwide, rather than only in museum collections and zoos is critical for understanding life, the 
workings of the biosphere and for developing methods to sustain the quality and longevity of human life. 
Of comparable importance, access to biodiversity as a living, evolving aspect of our planet has the poten-
tial to increase the public’s appreciation for these systems and processes.
Preserving biodiversity is in our self-interest. Nowhere does this ring truer than in drug discovery. The 
preservation of biodiversity provides a vital link to critically expand the molecular diversity necessary for 
successful drug discovery efforts in the future. Drug discovery from wild species has always been, and 
will continue to be one of the most critical for most if not all aspects of health care, disease prevention, 
and wellness [1]. In addition, chemical reagents, whether from natural or synthetic sources, are non-re-
newable, and using these reagents depletes future resources. Resources and knowledge (both traditional 
and modern scientific) about the ecology, taxonomy and usage of medicinally important organisms are 
too precious to squander. Consequently, all drug discovery programs, synthetic or natural, need to build 
the concept of sustainability into their research models.
Biodiversity therefore becomes critical to future drug discovery yet, there is alarming loss of biodiversity. 
Modern extinction rates are about 100 to 1000 times greater than extinction rates calculated over past 
eras [2]. Though new species are regularly discovered, known species go extinct at a rate 1000 times 
higher than the discovery of new species [3]. This ongoing loss of biodiversity is altering ecosystem func-
tions and the ability to provide goods and services for human health and well-being. In the case of drug 
discovery, according to some estimates, our planet is losing at least one important drug every two years 
[4]. Further, the irreversible loss of traditional knowledge on the medicinal use of plants and animals and 
the loss of molecular diversity is concomitant with the extinction of microbes, plants, fungi, and animals. 
The complementary losses threaten biomedical research, and in turn, the survival of humans.
The sustainable development of natural products will not be possible without taking biodiversity conser-
vation into consideration. While plants are commonly used for medicinal purposes, new possibilities are 
emerging from organisms that are incredibly diverse biologically and chemically, but relatively understud-
ied, such as arthropods and fungi, particularly in many countries deemed as ‘biodiversity hotspots’ [5]. 
We can be certain that we share the planet with an enormous variety of species. A very recent estimate of 
1-6 billion species is certainly realistic when we take into account parasites, parasitoids and endosymbi-
onts [6]. Knowing exactly where to look among all 
of this life, especially the hyper-diverse tax, and ob-
taining sufficient quantities of starting material have 
been an issue, historically, but new approaches and 
technology will surmount these stumbling blocks. 
Overall, the limitations of combinatorial chemistry 
and high-throughput screening, together with the 
promise of phenotype-based screening, transcrip-
tomics and synthetic biology suggest the arrival of 
a new era of drugs derived from natural extracts 
[7–10]. We believe that collecting, curating, and 
disseminating knowledge on biodiversity as it re-
lates to the treatment of human diseases will pro-
mote the conservation of bio- and molecular diver-
sity and, simultaneously, create the international 
cooperation needed to safeguard well-being for all 
communities.
Sound ethical oversight and responsible policy im-
plementation needs to accompany exploration of 
medicinal species, whether bacteria, fungi, plants or 
Increasing protection and responsible use of 
biodiversity will increase global health 
through discovery of new biomedically rele-
vant compounds.
Photo: Illustration created by Milica Pešić using CC0 Creative Commons images 
(no attribution required).
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The Bio2Bio consortium, composed of researchers from across the globe and from 
many disciplines, aims to develop new tools for protecting biodiversity whilst making 
new biomedical discoveries and empowering local communities.
animals, for drug discovery. In developing and low-income countries, there is a significant amount of bio-
diversity that is understudied and available for exploration. These areas are likely to be under dispropor-
tionate pressure as medical research turns to biodiverse areas for new drugs. Conversely, developed na-
tions have lost biodiversity while achieving economic progress [11]. Losing novel molecules at the expense 
of economic progress undermines solutions for human health and economic revenue for the communi-
ties where biodiversity should be protected most.
Future efforts to explore biodiversity for drug discovery must consider the interests of indigenous people, 
respect for their knowledge, and those living in developing, low-income countries. In developing coun-
tries, plants are a primary source of health care. When large pharmaceutical companies obtain medicinal 
plants or purchase lands that support their native habitat in order to make new drugs, these drugs and the 
plants themselves can become unavailable or unaffordable to the local people who will have no means to 
buy the products that are developed from these sources. Local plants, which contain mixtures of phyto-
chemicals used as herbal medicines, are far less expensive, and often more available to economically chal-
lenged communities than are compounds that are isolated, purified, standardized, and subjected to clinical 
trials. In addition, local communities may suffer because they may be displaced from culturally important 
traditional lands. Further, traditional knowledge of species properties and preparations may be lost as med-
ical research forces “western” values and approaches to medicine on diverse local populations.
At both the local and global scales, we should not satisfy our own needs at the expense of future genera-
tions, or indeed of other species on Earth. Ensuring the health and safety of other species is in our inter-
ests as a healthy planet for humans relies on a rich variety of species. Furthermore, ecosystem governance 
is also required if significant problems in biomedicine are to be solved through the analysis of global bio-
diversity.
To safeguard indigenous communities, protect biodiversity, and sustainably pursue drug discovery for the 
benefit of everyone, it is of paramount importance to strengthen the international implementation of the 
following practices:
•  Investigate and standardise natural products: therapeutic potential, chemistry, ecology, availability and 
potential to cultivate, traditional use, in situ and ex situ conservation, sustainable trade, and impacts by 
climate change, with special focus on indigenous medicinal species with potential therapeutic proper-
ties.
•  Implement ethical and governance models to engage with diverse indigenous communities to collect 
existing knowledge on species of interest, and create online databases for easy access, dissemination, 
and equitable distribution of benefits.
•  Promote open inter-disciplinary domestic and international dialogue and information sharing among 
academics, physicians, patients, policy-makers, commercial bodies, and local and indigenous commu-
nity stakeholders in the areas of medicine, health and wellbeing, with special focus on understanding 
different cultural norms and language needed to describe traditional medicine.
•  Establish best practices for sustainable natural product collection, production, storage, and prepara-
tion–with special attention to safeguard traditional family preparations and assurance that value is re-
turned to local communities, and standardise high capacity bio-molecular and cell-based assays in test-
ing these natural products.
•  Raise awareness of the long-term economic benefits of protecting biodiversity over the short-term ben-
efits of habitat destruction and unsustainable resource extraction.
•  Promote best practices in sustainable commercialisation of natural products that consider the balance 
of ecosystems and population needs and the implementation of a fair and equitable share of benefits 
among current and future stakeholders.
An urgent international and interdisciplinary initiative is required to promote partnerships among diverse 
stakeholders high, middle, and low-income countries to protect existing knowledge and biodiversity and 
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to support scientists in evaluating natural product-based therapeutic agents in a standardised and sustain-
able manner. Formation of multilateral, multidisciplinary research consortia that are global in scope is the 
pressing need to achieve these goals. Further, public-private partnerships will likely play key roles in ad-
dressing this challenge.
New funding models by international and government agencies, pharmaceutical companies, academic 
institutions, non-governmental organisations, scientific societies, and private foundations/donations are 
needed to promote work on:
•  Collecting, curating, and disseminating information locally, regionally, and globally, from various disci-
plines regarding historical, current, and potential use of the remaining species for control and preven-
tion and treatment of human diseases in order to promote research, protection, conservation, and in-
ternational cooperation.
•  Connect governmental, research and medical organisations focusing on collecting and testing natural 
products, developing biological and biomedical assays, health/nutrition regiments, ecological protocols, 
policy development, and such, to create a common understanding, standard protocols, and best prac-
tices in natural treatment and drug development in the interest of the survival of humans and other 
species.
In order to achieve the above goals, we have established a consortium of early-career scientists represent-
ing a wide range of disciplines and countries (Figure 1). The Bio2Bio (Biodiversity-to-Biomedicine) con-
sortium will 1) promote exchange of traditional and modern knowledge across disciplines and borders, 
2) build a unified framework for sharing resources and data while conforming to international treaties 
and local regulations, and 3) create an interdisciplinary knowledge hub to communicate research and 
empower the public, physicians, patients, and policymakers to create a unified approach to selecting, 
protecting, and undertaking research of the remaining wild species on our planet.
In conclusion, it is crucial that governments, global organizations, and local stakeholders come together 
to agree on preservation of remaining hotspots of biodiversity through development of partnerships. Ac-
tivities should include the collation and generation of knowledge about the regions and their species’ po-
tentials and provide education and collaborative outreach to local governments, decision makers, and 
stakeholders.
Figure 1. Schematic representation of the global and interdisciplinary nature of our proposal. Names of the selected 
research subjects to be included in our consortium are indicated over the globe/map of the world in the shape of 'Tao', 
with disciplines being distributed according to their relation to each other, in the context of our initiative, to form two 
large interconnected groups 'Global South' and 'Global North', characteristic by overall tendency to 'biodiversity and 
traditional knowledge' and 'technology and modern knowledge', respectively. The metaphorical relation to the ancient 
and modern Chinese symbol of 'Tao' is demonstrating the holistic or 'non-dualistic' approach to the solution to 
biodiversity and biomedicine problems, requiring acknowledgement and cooperation of bigger scientific community 
in order to promote mutually beneficial co-existence of humankind with other species.
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This largely academic group will also seek to engage individuals and organisations outside of academia 
via our extended professional networks to help meet the objectives of the consortium. In addition, we 
invite new members, contributors, and funding opportunities. If you would like to learn more, please 
contact us at info@bio2bio.net. Together, we can create a new paradigm in protecting biodiversity for 
sustainable drug discovery that will benefit humanity and the planet.
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